High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma

Smoothened is a poor prognosis factor and a potential therapeutic target in glioma

(2017) Yiming Tu et al.   Scientific Reports

Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia

(2016) Nisar A. Amin et al.   CLINICAL CANCER RESEARCH

Immune phenotypes predict survival in patients with glioblastoma multiforme

(2016) Haouraa Mostafa et al.   Journal of Hematology & Oncology

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

(2016) Xuejiao Liu et al.   Journal of Hematology & Oncology

The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells

(2016) Zeyou Wang et al.   Journal of Hematology & Oncology

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation

(2016) E Grassilli et al.   ONCOGENE

Negative regulation of NF-κB p65 activity by serine 536 phosphorylation

(2016) Jean-Philippe Pradère et al.   Science Signaling

Negative regulation of NF-κB p65 activity by serine 536 phosphorylation

(2016) Jean-Philippe Pradère et al.   Science Signaling

Targeting NF- B in glioblastoma: A therapeutic approach

(2016) D. Friedmann-Morvinski et al.   Science Advances

Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import

(2015) Mingshan Niu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells

(2015) Mingshan Niu et al.   CANCER BIOLOGY & THERAPY

Eva1 Maintains the Stem-like Character of Glioblastoma-Initiating Cells by Activating the Noncanonical NF- B Signaling Pathway

(2015) N. Ohtsu et al.   CANCER RESEARCH

TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion

(2015) Bin Li et al.   Journal of Hematology & Oncology

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling

(2015) Evan M Cherry et al.   Molecular Cancer

Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy

(2015) Kirk E. Cahill et al.   NEURO-ONCOLOGY

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling

(2014) J Hu et al.   ONCOGENE

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

(2013) J. A. Woyach et al.   BLOOD

Erratum: Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2013) The Cancer Genome Atlas Research Network   NATURE

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

(2013) Rami Rahal et al.   NATURE MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

(2011) R Bonavia et al.   ONCOGENE

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE